Roberto Patuzzo

Roberto Patuzzo

Auto-generated profile, based on publicly available information

Roberto Patuzzo

Melanoma and Sarcoma Unit, Department of Surgery, National Tumor Institute, Milan, Italy

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2015 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Closed access
PDF file
RDRiccardo Danielli
Riccardo Danielli
RPRoberto Patuzzo
Roberto Patuzzo
AGAnna Maria Di Giacomo
Anna Maria Di Giacomo
GGGianfranco Gallino
Gianfranco Gallino
AMAndrea Maurichi
Andrea Maurichi
MSMario Santinami
Mario Santinami

20 September 2006 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
NCNatale Cascinelli
Natale Cascinelli
EBEmilio Bombardieri
Emilio Bombardieri
RBRosaria Bufalino
Rosaria Bufalino
TCTiziana Camerini
Tiziana Camerini
Antonino CarboneAntonino Carbone
Antonino Carbone
GTGabrina Tragni
Gabrina Tragni
Purpose: To evaluate the prognostic significance of sentinel node biopsy in the management of stage IB and II melanoma patients, and to evaluate the status of nonsentinel nodes as a “second step key factor” to assess the prognosis of these patients. Patients and Methods: We conducted an analysis of data collected in a prospective database. Results: From February 1994 to June 2005, 1,108 consecutive patients with stage IB and II melanoma were submitted to sentinel node biopsy; 176 patients (15.9%) had occult node metastases. The frequency of positive nodes increased with increasing Breslow's thickness. The largest diameter of metastatic foci and their localization within the lymph node were associated with the risk of nonsentinel node metastases only. The 5-year survival of patients with positive sentinel nodes was 81.4% in patients with one positive node and 39.6% in patients with two positive nodes (P = .056). Multivariate analysis indicated that status of sentinel nodes is a key factor and that sex and Breslow's thickness maintain statistically significant relevance. Ulceration, which was associated with survival when considered as single factor (P < .001) had no impact on survival in the multivariate analysis (P = .10). To evaluate the relevance of metastases to nonsentinel nodes, we identified four groups of patients. Conclusion: Evaluation of the sentinel node is a useful procedure to identify patients to be submitted for complete lymph node dissection. The procedure makes it possible to assess the best prognosis of patients.

8 October 2005 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Closed access
PDF file
LPLorenzo Pilla
Lorenzo Pilla
RPRoberto Patuzzo
Roberto Patuzzo
LRLicia Rivoltini
Licia Rivoltini
MMMichele Maio
Michele Maio
EPElisabetta Pennacchioli
Elisabetta Pennacchioli
GPGiorgio Parmiani
Giorgio Parmiani

10 August 2014 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
AMAndrea Maurichi
Andrea Maurichi
RMRosalba Miceli
Rosalba Miceli
TCTiziana Camerini
Tiziana Camerini
LMLuigi Mariani
Luigi Mariani
RPRoberto Patuzzo
Roberto Patuzzo
MSMario Santinami
Mario Santinami
Purpose: Cutaneous melanoma incidence is increasing. Most new cases are thin (≤ 1 mm) with favorable prognoses, but survival is nonetheless variable. Our aim was to investigate new prognostic factors and construct a nomogram for predicting survival in individual patients. Patients and Methods: Data from 2,243 patients with thin melanoma were retrieved from prospectively maintained databases at six centers. Kaplan-Meier survival and crude cumulative incidences of recurrence were estimated, and competing risks were taken into account. Multivariable Cox regression was used to investigate survival predictors. Results: Median follow-up was 124 months (interquartile range, 106 to 157 months); 12-year overall survival was 85.3% (95% CI, 83.4% to 87.2%). Median times to local, regional, and distant recurrence were 79, 78, and 107 months, respectively. Relapse was significantly related to age, Breslow thickness, mitotic rate (MR), ulceration, lymphovascular invasion (LVI), and regression; incidence was lower and subgroup differences were less marked for distant metastasis than for regional relapse. The worst prognosis categories were age older than 60 years, Breslow thickness more than 0.75 mm, MR ≥ 1, presence of ulceration, presence of LVI, and regression ≥ 50%. Breslow thickness more than 0.75 mm, MR ≥ 1, presence of ulceration, and LVI (all P = .001) were significantly associated with sentinel node positivity. Age, MR, ulceration, LVI, regression, and sentinel node status were independent predictors of survival and were used to construct a nomogram to predict 12-year overall survival. The nomogram was well calibrated and had good discriminative ability (adjusted Harrell C statistic, 0.88). Conclusion: Our findings suggest including LVI and regression as new prognostic factors in the melanoma staging system. The nomogram appears useful for risk stratification in clinical management and for recruiting patients to clinical trials.

1 May 2006 in Cancer Research
Verified
Journal Article
Open access
PDF file
TPTiziana Di Pucchio
Tiziana Di Pucchio
LPLorenzo Pilla
Lorenzo Pilla
ICImerio Capone
Imerio Capone
MFMaria Ferrantini
Maria Ferrantini
EMEnrica Montefiore
Enrica Montefiore
LRLicia Rivoltini
Licia Rivoltini
The use of IFN-α in clinical oncology has generally been based on the rationale of exploiting its antiproliferative and antiangiogenic activities. However, IFN-α also exhibits enhancing effects on T-cell and dendritic cell functions, which may suggest a novel use as a vaccine adjuvant. We have carried out a pilot phase I-II trial to determine the effects of IFN-α, administered as an adjuvant of Melan-A/MART-1:26-35(27L) and gp100:209-217(210M) peptides, on immune responses in stage IV melanoma patients. In five of the seven evaluable patients, a consistent enhancement of CD8+ T cells recognizing modified and native MART-1 and gp100 peptides and MART-1+gp100+ melanoma cells was observed. Moreover, vaccination induced an increase in CD8+ T-cell binding to HLA tetramers containing the relevant peptides and an increased frequency of CD45RA+CCR7− (terminally differentiated effectors) and CD45RA−CCR7− (effector memory) cells. In all patients, treatment augmented significantly the percentage of CD14+ monocytes and particularly of the CD14+CD16+ cell fraction. An increased expression of CD40 and CD86 costimulatory molecules in monocytes was also observed. Notably, postvaccination monocytes from two of the three patients showing stable disease or long disease-free survival showed an enhanced antigen-presenting cell function and capability to secrete IP10/CXCL10 when tested in mixed leukocyte reaction assays, associated to a boost of antigen and melanoma-specific CD8+ T cells. Although further clinical studies are needed to show the adjuvant activity of IFN-α, the present data represent an important starting point for considering a new clinical use of IFN-α and new immunologic end points, potentially predictive of clinical response. (Cancer Res 2006; 66(9): 4943-51)

27 March 2007 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
MDMaria Daniotti
Maria Daniotti
VVViviana Vallacchi
Viviana Vallacchi
LRLicia Rivoltini
Licia Rivoltini
RPRoberto Patuzzo
Roberto Patuzzo
MSMario Santinami
Mario Santinami
Monica RodolfoMonica Rodolfo
Monica Rodolfo
BRAFV600E is the most represented somatic point mutation in cutaneous melanoma, thus providing a unique molecular marker for this disease. The development of efficient methods for its detection in free circulating DNA of patients may lead to the improvement of diagnostic and prognostic tools. With this aim, we evaluated whether BRAFV600E represents a detectable marker in the plasma/serum from melanoma patients in a pilot study. Circulating cell‐free DNA was extracted from the serum or plasma of 15 healthy donors and 41 melanoma patients at different clinical stages and obtained either presurgery or after surgery during follow‐up. Quantitative analysis showed higher levels of circulating free DNA in patients compared to controls, with the highest levels detected in samples obtained presurgery and at stage IV. Four different PCR methods were compared for their capacity to amplify a few copies of BRAFV600E in wild‐type DNA. BRAFV600E was detectable in circulating DNA of 12 patients and in none of the controls; only 1 PCR method reproducibly amplified BRAFV600E. Positive samples were obtained from 8/13 patients at stage IV and from 4/24 patients at stage III, but not in 4 patients at stage I–II; half of the positives were obtained presurgery and half at follow‐up. Correspondence between circulating DNA and related tumors were examined for 20 patients, and a correlation was found for stage IV patients. In conclusion, this method can be utilized for monitoring the disease in stage IV melanoma patients but it appears unsatisfactory for the early detection of melanoma.